Subdued Growth No Barrier To Tong Ren Tang Technologies Co. Ltd.'s (HKG:1666) Price
It's not a stretch to say that Tong Ren Tang Technologies Co. Ltd.'s (HKG:1666) price-to-earnings (or "P/E") ratio of 10.7x right now seems quite "middle-of-the-road" compared to the market in Hong K
同仁堂科技:年報2023
Stable sector+product space, Tongrentang Technology (01666.HK)'s dual market potential
As we all know, in the Hong Kong stock market, Chinese medicine stocks have been undervalued for a long time. Judging from the net market ratio, the net market ratio of the entire traditional Chinese medicine concept is less than 1 times. A large part of the reason behind this is that investors in the Hong Kong stock market, especially foreign investors, have long had no understanding of traditional Chinese medicine or traditional Chinese medicine, and even misunderstood the introduction of animals and plants into medicine.
Is Tong Ren Tang Technologies (HKG:1666) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Tong Ren Tang Technologies Co. Ltd. Non-GAAP EPS of C$0.43, Revenue of C$23.89M
Tung Yan Tong Technology Announces 2023 Annual Results
BEIJING, MARCH 25, 2024 /NEWS MEDIA/ -- BEIJING TONGRENTANG TECHNOLOGY DEVELOPMENT CO., LTD. (“TONG YANTANG TECHNOLOGY” OR THE “GROUP”, 1666.HK) IS PLEASED TO ANNOUNCE THE GROUP'S AUDITED CONSOLIDATED RESULTS FOR THE YEAR ENDED 31 DECEMBER 2013. In 2013, the Group achieved revenues of RMB67.7 billion, an increase of 13.04% year-on-year; achieved net net income of RMB5.9 billion, an increase of 1.25% year-on-year; in terms of products, the Group sold 62 products of more than RMB 500 million and sales of more than RMB 1 billion.
Good sector+performance catalyst, explaining in detail the differences in Tongrentang Technology (01666.HK)'s dual market expectations
Under a series of favorable policies, Tong Ren Tang Technology, as a highly recognizable and even scarce enterprise in the Hong Kong stock market, will benefit.
Tongrentang Technology (01666.HK)'s 2023 revenue of 6.773 billion yuan increased 13.04% year-on-year
Gelonghui, March 22丨Tong Ren Tang Technology (01666.HK) announced that for the year ended December 31, 2023, the Group's revenue was RMB 6.773 billion, up 13.04% year on year; net profit attributable to company owners was RMB 590 million, up 1.25% over the same period last year; earnings per share was RMB 0.46 (2022: RMB 0.46); and dividend per share was RMB 0.18 (2022: RMB 0.16). Throughout the year, the Group is committed to adapting to the new normal in the traditional Chinese medicine industry, continuing to focus on core competitive advantages, and advancing
Tongrentang Technology (01666) announced annual results. Profit attributable to shareholders of 590 million yuan increased 1.25% year-on-year, and final dividend of 0.18 yuan per share
Tong Ren Tang Technology (01666) announced its annual results for the year ended December 31, 2023. The group obtained revenue of RMB 6.773 billion (same unit), an increase of 13.04% year on year; profit attributable to company owners of RMB 590 million, an increase of 1.25% year on year; earnings per share of 0.46 yuan, and plans to pay a final dividend of RMB 0.18 per share.
TONG REN TANG: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
TONG REN TANG: ANNOUNCEMENT ON RESULTS OF SUBSIDIARY; AND REVISED DIVIDEND POLICY OF SUBSIDIARY
Tong Ren Tang Technology (01666.HK) held a board meeting on March 22 to consider and approve the annual results
Tong Ren Tang Technology (01666.HK) announced that the board meeting will be held on March 22, 2024 (Friday) at No. 20, South Third Ring Road, Fengtai District, Beijing, People's Republic of China.
TONG REN TANG: NOTICE OF BOARD MEETING
Tong Ren Tang Technology (01666.HK) and Tong Ren Tang Digital Technology signed an e-commerce service cooperation framework agreement
Gelonghui March 11 | Tong Ren Tang Technology (01666.HK) announced that the company signed an e-commerce service cooperation framework agreement with Tong Ren Tang Digital Technology on March 11, 2024. According to the e-commerce service cooperation framework agreement, Tong Ren Tang Digital Technology agreed to provide e-commerce services to the Group.
Announcement Highlights | NIO's Q4 revenue increased 6.5% year on year to 17.103 billion yuan; Great Wall Motor's February sales increased 4.12% year on year
China Electric Power's combined total electricity sales volume in January was 10.3482 million megawatt-hours, an increase of 41.15% over the previous year; Shanghai Pharmaceutical: Norepinephrine bitartrate injection passed the generic drug consistency evaluation.
Tong Ren Tang Technology (01666): Obtaining a notice of approval for clinical trials of drugs
Tongrentang Technology (01666) issued an announcement. The company's pharmaceutical factory recently received the “Drug...” issued by the State Drug Administration
Tong Ren Tang Technology (01666) fell 4.30% and now reports 5.160 yuan, a 52-week low
As of 16:08, Tong Ren Tang Technology (01666) fell 4.30% from yesterday's closing price and now reports a 52-week low of 5.160 yuan; the trading volume was 19.98 million shares, with a turnover of HK$10.4796 million.
The Five-year Shareholder Returns and Company Earnings Persist Lower as Tong Ren Tang Technologies (HKG:1666) Stock Falls a Further 6.9% in Past Week
For many, the main point of investing is to generate higher returns than the overall market. But the main game is to find enough winners to more than offset the losers So we wouldn't blame long term
Tong Ren Tang Technologies' 2023 Profit to Slip Up to 7%
Tong Ren Tang Technologies (HKG:1666) warned that its net profit attributable to owners is expected to slip from 3% to 7% in 2023. The Chinese medicine distributor attributed the forecast to a slowdow
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
No Data